234 related articles for article (PubMed ID: 32733801)
1. Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case Report.
Guida M; D'Alò A; Mangia A; Di Pinto F; Sonnessa M; Albano A; Sciacovelli A; Asabella AN; Fucci L
Front Oncol; 2020; 10():1073. PubMed ID: 32733801
[No Abstract] [Full Text] [Related]
2. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.
Torchio M; Cattaneo L; Milione M; Prinzi N; Corti F; Ungari M; Anichini A; Mortarini R; Occhini A; Bertino G; Maurichi A; Coppa J; Di Bartolomeo M; de Braud FG; Pusceddu S
Front Oncol; 2021; 11():628324. PubMed ID: 34221958
[TBL] [Abstract][Full Text] [Related]
4. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors: an alternative treatment target for advanced Merkel cell carcinoma.
Br J Dermatol; 2021 Feb; 184(2):e32-e52. PubMed ID: 33544438
[TBL] [Abstract][Full Text] [Related]
6. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
7. Merkel Cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract][Full Text] [Related]
8. Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report.
Leão I; Marinho J; Costa T
World J Clin Cases; 2021 Jun; 9(18):4829-4836. PubMed ID: 34222455
[TBL] [Abstract][Full Text] [Related]
9. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
10. Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies.
Villani A; Fabbrocini G; Costa C; Carmela Annunziata M; Scalvenzi M
Dermatol Ther (Heidelb); 2019 Jun; 9(2):209-222. PubMed ID: 30820877
[TBL] [Abstract][Full Text] [Related]
11. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
12. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma.
Akaike T; Qazi J; Anderson A; Behnia FS; Shinohara MM; Akaike G; Hippe DS; Thomas H; Takagishi SR; Lachance K; Park SY; Tarabadkar ES; Iyer JG; Blom A; Parvathaneni U; Vesselle H; Nghiem P; Bhatia S
Br J Dermatol; 2021 Feb; 184(2):319-327. PubMed ID: 32320473
[TBL] [Abstract][Full Text] [Related]
13. Merkel cell carcinoma.
Mistry K; Levell NJ; Craig P; Steven NM; Venables ZC
Skin Health Dis; 2021 Dec; 1(4):e55. PubMed ID: 35663768
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.
Femia D; Prinzi N; Anichini A; Mortarini R; Nichetti F; Corti F; Torchio M; Peverelli G; Pagani F; Maurichi A; Mattavelli I; Milione M; Bedini N; Corti A; Di Bartolomeo M; de Braud F; Pusceddu S
Target Oncol; 2018 Oct; 13(5):567-582. PubMed ID: 30073632
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
16. Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature.
Kritikos N; Priftakis D; Stavrinides S; Kleanthous S; Sarafianou E
Oncol Lett; 2015 Sep; 10(3):1610-1616. PubMed ID: 26622719
[TBL] [Abstract][Full Text] [Related]
17. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
18. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
19. Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma.
Principe DR; Clark JI; Emami B; Borowicz S
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31439556
[TBL] [Abstract][Full Text] [Related]
20. Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma.
Aicher A; Sindrilaru A; Crisan D; Thaiss W; Steinacker J; Beer M; Wiegel T; Scharffetter-Kochanek K; Beer AJ; Prasad V
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
